Increase of cyclooxygenase-2 inhibition with celecoxib combined with 5-FU enhances tumor cell apoptosis and antitumor efficacy in a subcutaneous implantation tumor model of human colon cancer
被引:29
作者:
论文数: 引用数:
h-index:
机构:
Zhang, De-Qing
[1
]
论文数: 引用数:
h-index:
机构:
Guo, Qiang
[2
]
论文数: 引用数:
h-index:
机构:
Zhu, Jian-Hong
[1
]
论文数: 引用数:
h-index:
机构:
Chen, Wei-Chang
[1
]
机构:
[1] Soochow Univ, Affiliated Hosp 1, Dept Digest Internal Med, Suzhou 215006, Jiangsu, Peoples R China
[2] Soochow Univ, Affiliated Hosp 1, Dept Emergency & Intens Care Unit, Suzhou 215006, Jiangsu, Peoples R China
Background: The purpose of this study was to investigate the anti-tumor effect and explore the mechanisms of celecoxib (a selective cyclooxygenase-2 inhibitor) combined with 5-fluorouracil (5-FU) on the treatment of human colorectal cancer in a BALB/C nude mouse subcutaneous xenograft model. Methods: Effects of celecoxib combined with 5-FU on the proliferation of xenograft carcinoma induced by HT 29 were investigated. The apoptotic cells were detected by electron microscope and TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) assay. Immunohistochemistry and Western blot were used to estimate the expression of cytochrome C, caspase-3 and caspase-9. Results: Compared with the control group, treatment groups showed significant inhibition of tumor growth. More apoptotic cells existed after treatment with celecoxib combined with 5-FU. Cytochrome C, caspase-3 and caspase-9 were increased in treated groups, and more obviously in the drug combination group. Cyclooxygenase-2 (COX-2) were decreased after treatment with celecoxib only or combined with 5-FU. And the combined group showed a greater decrease. Conclusions: Celecoxib combined with 5-FU could inhibit the growth of tumors in vivo by inducing apoptosis and activation of the cytochrome C dependency apoptosis signal pathway. A decrease of COX-2 and an increase of cytochrome C, caspase-3 and caspase-9 may be involved in this process.
机构:
Kanazawa Univ, Grad Sch Med Sci, Dept Oncol, Div Canc Med, Kanazawa, Ishikawa 9208641, JapanKanazawa Univ, Grad Sch Med Sci, Dept Oncol, Div Canc Med, Kanazawa, Ishikawa 9208641, Japan
Fujimura, Takashi
;
Ohta, Tetsuo
论文数: 0引用数: 0
h-index: 0
机构:
Kanazawa Univ, Grad Sch Med Sci, Dept Oncol, Div Canc Med, Kanazawa, Ishikawa 9208641, JapanKanazawa Univ, Grad Sch Med Sci, Dept Oncol, Div Canc Med, Kanazawa, Ishikawa 9208641, Japan
Ohta, Tetsuo
;
Oyama, Katsunobu
论文数: 0引用数: 0
h-index: 0
机构:
Kanazawa Univ, Grad Sch Med Sci, Dept Oncol, Div Canc Med, Kanazawa, Ishikawa 9208641, JapanKanazawa Univ, Grad Sch Med Sci, Dept Oncol, Div Canc Med, Kanazawa, Ishikawa 9208641, Japan
Oyama, Katsunobu
;
Miyashita, Tomoharu
论文数: 0引用数: 0
h-index: 0
机构:
Kanazawa Univ, Grad Sch Med Sci, Dept Oncol, Div Canc Med, Kanazawa, Ishikawa 9208641, JapanKanazawa Univ, Grad Sch Med Sci, Dept Oncol, Div Canc Med, Kanazawa, Ishikawa 9208641, Japan
机构:
Kanazawa Univ, Grad Sch Med Sci, Dept Oncol, Div Canc Med, Kanazawa, Ishikawa 9208641, JapanKanazawa Univ, Grad Sch Med Sci, Dept Oncol, Div Canc Med, Kanazawa, Ishikawa 9208641, Japan
Fujimura, Takashi
;
Ohta, Tetsuo
论文数: 0引用数: 0
h-index: 0
机构:
Kanazawa Univ, Grad Sch Med Sci, Dept Oncol, Div Canc Med, Kanazawa, Ishikawa 9208641, JapanKanazawa Univ, Grad Sch Med Sci, Dept Oncol, Div Canc Med, Kanazawa, Ishikawa 9208641, Japan
Ohta, Tetsuo
;
Oyama, Katsunobu
论文数: 0引用数: 0
h-index: 0
机构:
Kanazawa Univ, Grad Sch Med Sci, Dept Oncol, Div Canc Med, Kanazawa, Ishikawa 9208641, JapanKanazawa Univ, Grad Sch Med Sci, Dept Oncol, Div Canc Med, Kanazawa, Ishikawa 9208641, Japan
Oyama, Katsunobu
;
Miyashita, Tomoharu
论文数: 0引用数: 0
h-index: 0
机构:
Kanazawa Univ, Grad Sch Med Sci, Dept Oncol, Div Canc Med, Kanazawa, Ishikawa 9208641, JapanKanazawa Univ, Grad Sch Med Sci, Dept Oncol, Div Canc Med, Kanazawa, Ishikawa 9208641, Japan